It is widely accepted that insufficient insulin-stimulated activation of muscle glycogen synthesis is one of the major components of non-insulindependent (type 2) diabetes mellitus. Glycogen synthase, a key enzyme in muscle glycogen synthesis, is extensively regulated, both allosterically (by glucose-6-phosphate, ATP, and others) and covalently (by phosphorylation). Although glycogen synthase has been a topic of intense study for more than 50 years, its kinetic characterization has been confounded by its large number of phosphorylation states. Questions remain regarding the function of glycogen synthase regulation and the relative importance of allosteric and covalent modification in fulfilling this function. In this review, we consider both earlier kinetic studies and more recent site-directed mutagenesis and crystal structure studies in a detailed qualitative discussion of the effects of regulation on the kinetics of glycogen synthase. We propose that both allosteric and covalent modification of glycogen synthase may be described by a Monod-Wyman-Changeux model in terms of apparent changes to L, the equilibrium constant for transition between the T and R conformers. As, with the exception of L, all parameters of this model are independent of the glycogen synthase phosphorylation state, the need to determine kinetic parameters for all possible states is eliminated; only the relationship between a particular state and L must be established. We conclude by suggesting that renewed efforts to characterize the relationship between phosphorylation and the kinetics of glycogen synthase are essential in order to obtain a better quantitative understanding of the function of glycogen synthesis regulation. The model we propose may prove useful in this regard.Abbreviations ADP-Glc, ADP-glucose; AMPK, AMP-activated protein kinase; AtGS, Agrobacterium tumefaciens glycogen synthase; CaMKII, calmodulindependent protein kinase II; CK1, casein kinase 1; CK2, casein kinase 2; D form, glucose-6-phosphate-dependent form of glycogen synthase; DYRK, dual-specificity tyrosine-phosphorylated and tyrosine-regulated protein kinase; EcGS, Escherichia coli glycogen synthase; G6P, glucose-6-phosphate; GP, glycogen phosphorylase; GS, glycogen synthase; GSK3, glycogen synthase kinase 3; I form, glucose-6-phosphate-independent form of glycogen synthase; MWC, Monod-Wyman-Changeux; p38MAPK, mitogen-activated protein kinase; PaGS, Pyrococcus abyssi glycogen synthase; PASK, Per/Arnt/Sim domain-containing protein kinase; PhK, phosphorylase kinase; PKA, cAMPdependent protein kinase; PP1, protein phosphatase 1; PP2A, protein phosphatase 2A; ScGS, Saccharomyces cerevisiae glycogen synthase; UDP-Glc, uridine diphosphate glucose.

The enzymes in the Embden-Meyerhof-Parnas pathway of Plasmodium falciparum trophozoites were kinetically characterized and their integrated activities analyzed in a mathematical model. For validation of the model, we compared model predictions for steady-state fluxes and metabolite concentrations of the hexose phosphates with experimental values for intact parasites. The model, which is completely based on kinetic parameters that were measured for the individual enzymes, gives an accurate prediction of the steady-state fluxes and intermediate concentrations. This is the first detailed kinetic model for glucose metabolism in P. falciparum, one of the most prolific malaria-causing protozoa, and the high predictive power of the model makes it a strong tool for future drug target identification studies. The modelling workflow is transparent and reproducible, and completely documented in the SEEK platform, where all experimental data and model files are available for download.

Several enzymes have been described that undergo both allosteric and covalent regulation, but, to date, there exists no succinct kinetic description that is able to account for both of these mechanisms of regulation. Muscle glycogen synthase, an enzyme implicated in the pathogenesis of several metabolic diseases, is activated by glucose 6-phosphate and inhibited by ATP and phosphorylation at multiple sites. A kinetic description of glycogen synthase could provide insight into the relative importance of these modifiers. In the present study we show, using non-linear parameter optimization with robust weight estimation, that a Monod-Wyman-Changeux model in which phosphorylation favours the inactive T conformation provides a satisfactory description of muscle glycogen synthase kinetics. The best-fit model suggests that glucose 6-phosphate and ATP compete for the same allosteric site, but that ATP also competes with the substrate UDP-glucose for the active site. The novelty of our approach lies in treating covalent modification as equivalent to allosteric modification. Using the obtained rate equation, the relationship between enzyme activity and phosphorylation state is explored and shown to agree with experimental results. The methodology we propose could also be applied to other enzymes that undergo both allosteric and covalent modification.

We propose a hierarchical modelling approach to construct models for disease states at the whole-body level. Such models can simulate effects of drug-induced inhibition of reaction steps on the whole-body physiology. We illustrate the approach for glucose metabolism in malaria patients, by merging two detailed kinetic models for glucose metabolism in the parasite Plasmodium falciparum and the human red blood cell with a coarse-grained model for whole-body glucose metabolism. In addition we use a genome-scale metabolic model for the parasite to predict amino acid production profiles by the malaria parasite that can be used as a complex biomarker.

No abstract